79099-04-0

Basic information

• Product Name: 3-(1-Benzylpiperidin-4-yl)-3,4-dihydro-1H-2$l^{6},1,3-benzothiadiazine-2,2-dione
• Synonyms: 3-(1-Benzylpiperidin-4-yl)-3,4-dihydro-1H-2$l^{6},1,3-benzothiadiazine-2,2-dione;3-(1-Benzylpiperidin-4-yl)-3,4-dihydro-1H-2,1,3-benzothiadiazine 2,2-dioxide;3-(1-Benzylpiperidin-4-yl)-3,4-dihydro-1H-2LAMBDA(6),1,3-benzothiadiazine-2,2-dione
• CAS NO: 79099-04-0
• Molecular Formula: C₁₉H₂₃N₃O₂S
• Molecular Weight: 357.46982
• Mol File: 79099-04-0.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-(1-Benzylpiperidin-4-yl)-3,4-dihydro-1H-2$l^{6},1,3-benzothiadiazine-2,2-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(1-Benzylpiperidin-4-yl)-3,4-dihydro-1H-2$l^{6},1,3-benzothiadiazine-2,2-dione(79099-04-0)
• EPA Substance Registry System: 3-(1-Benzylpiperidin-4-yl)-3,4-dihydro-1H-2$l^{6},1,3-benzothiadiazine-2,2-dione(79099-04-0)

Safety Data

• Hazardous Substances Data: 79099-04-0(Hazardous Substances Data)

Upstream product

• 79099-03-9 2-amino-N-[1-(phenylmethyl)-4-piperidinyl]-benzenemethanamine 
• 7803-58-9 SULFAMIDE 

Relevant articles and documents

Calcitonin gene related peptide receptor antagonists

The present invention relates to compounds of Formula (I) as antagonists of calcitonin gene-related peptide receptors (“CGRP-receptor”), pharmaceutical compositions comprising them, methods for identifying them, methods of treatment using them and their use in therapy for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.

Modified aminoacids, pharmaceuticals containing these compounds and method for their production

The present invention relates to modified amino acids of general formula wherein A, Z, X, n, m, R, R2, R3, R4and R11are defined as in claims 1 to 5, their tautomers, their diastereomers, their enantiomers, the mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, pharmaceutical compositions containing these compounds, the use thereof and processes for preparing them as well as their use for the production and purification of antibodies and as labelled compounds in RIA- and ELISA assays and as diagnostic or analytical aids in neurotransmitter research.

Piperidine derivatives

New piperidine derivatives which have a useful pharmacological activity such as hypotensive activity are prepared.